利妥昔单抗联合或不联合含类固醇化疗的快速输注：单一机构的1年经验。
Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
作者信息
Salar Antonio, Casao Dolors, Cervera Marta, Pedro Carmen, Calafell Montserrat, Abella Eugenia, Alvarez-Larrán Alberto, Besses Carlos
机构信息
Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain.
出版信息
Eur J Haematol. 2006 Oct;77(4):338-40. doi: 10.1111/j.1600-0609.2006.00713.x. Epub 2006 Jul 19.
UNLABELLED
We assessed the feasibility of a rapid infusion of rituximab with or without steroid-containing chemotherapy.
INCLUSION CRITERIA
previous infusion of rituximab without grade 3 or 4 toxicity, lymphoid cells <5 x 10(9)/L and rituximab dose of 375 mg/m(2). Seventy patients were treated with a total of 319 rapid rituximab infusions [126 (40%) with and 193 (60%) without steroids]. Overall, rapid infusion of rituximab was well tolerated - there were no grade 3 or 4 adverse events. Only, three patients developed symptoms, all grade 1. In conclusion, rituximab administration in a 90-min infusion schedule is well tolerated and safe, both in patients who are administered steroids and in patients who are not.
未标记
我们评估了快速输注利妥昔单抗联合或不联合含类固醇化疗的可行性。
纳入标准
既往输注利妥昔单抗无3级或4级毒性，淋巴细胞<5×10⁹/L且利妥昔单抗剂量为375mg/m²。70例患者共接受了319次利妥昔单抗快速输注[126次（40%）联合类固醇，193次（60%）不联合类固醇]。总体而言，利妥昔单抗快速输注耐受性良好——无3级或4级不良事件。仅3例患者出现症状，均为1级。总之，无论是接受类固醇治疗的患者还是未接受类固醇治疗的患者，90分钟输注方案的利妥昔单抗给药耐受性良好且安全。
Zotero 插件